Erasca reported favorable safety and tolerability with no dose-limiting toxicities and predominantly low-grade adverse events across all dose levels. Initial Phase 1 monotherapy data for ERAS-0015 are ...
Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...
VANCOUVER, BC / ACCESS Newswire / January 14, 2026 / Future Fuels Inc. (TSXV:FTUR)(FSE:S0J)(OTCQX:FTURF) ("Future Fuels" or the "Company") is pleased to announce the results of its 2025 ground gravity ...
American Tungsten Corp. (CSE: TUNG) (OTCQB: TUNGF) (FSE: RK90) ("American Tungsten" or the "Company) is pleased to announce an update on advancing the underground drill program at the IMA mine. To ...
BRISBANE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at ...
Following completion of the 2025 re-assay program, the Berg database contains 26,797 unique assay intervals, of which 22,138 samples, or 82.6%, now include gold and silver analyses. This represents a ...
Sun Point requires live observation, outcomes tracking, and systemic supervision for every therapist—because clients deserve accountability. Gatekeeping is what sets Sun Point apart. Every clinical ...
ACNP abstracts are available on the conference website and the Company’s poster will be available on the Centessa website at https://investors.centessa.com/events-presentations after the poster ...
17hOpinion
The Cost of Trump's Tariffs Is Not Just Financial: It's the Uncertainty They Bring, Part 1
In this first in a three-part series, trends in the trade enforcement and compliance landscape, a fast-moving area marked by ...
Premier American Uranium Inc. ("PUR", the "Company" or "Premier American Uranium"- (TSXV: PUR) (OTCQB: PAUIF) is pleased to ...
Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –– Internal GMP manufacturing capable of supporting pivotal trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback